USANA Health Sciences, Inc. (NYSE:USNA) Director Gilbert A. Fuller sold 1,710 shares of the firm’s stock in a transaction that occurred on Thursday, October 26th. The shares were sold at an average price of $67.01, for a total transaction of $114,587.10. Following the completion of the transaction, the director now directly owns 1,710 shares in the company, valued at $114,587.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
USANA Health Sciences, Inc. (NYSE USNA) opened at 65.70 on Wednesday. The company has a market capitalization of $1.61 billion, a PE ratio of 17.06 and a beta of 1.09. The firm has a 50-day moving average of $59.88 and a 200-day moving average of $60.81. USANA Health Sciences, Inc. has a 52 week low of $52.55 and a 52 week high of $71.00.
USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.02 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.91 by $0.11. USANA Health Sciences had a net margin of 8.79% and a return on equity of 26.54%. The firm had revenue of $261.77 million during the quarter, compared to analysts’ expectations of $259.52 million. During the same period in the prior year, the company posted $2.40 EPS. The company’s revenue was up 3.0% on a year-over-year basis. Equities analysts expect that USANA Health Sciences, Inc. will post $3.92 earnings per share for the current fiscal year.
USANA Health Sciences announced that its board has authorized a stock buyback program on Tuesday, July 25th that permits the company to buyback $64.60 million in shares. This buyback authorization permits the company to repurchase up to 46% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its stock is undervalued.
Several institutional investors and hedge funds have recently bought and sold shares of USNA. Victory Capital Management Inc. increased its position in shares of USANA Health Sciences by 124.7% during the first quarter. Victory Capital Management Inc. now owns 2,117 shares of the company’s stock worth $122,000 after buying an additional 1,175 shares during the period. BNP Paribas Arbitrage SA increased its position in shares of USANA Health Sciences by 13.1% during the second quarter. BNP Paribas Arbitrage SA now owns 2,111 shares of the company’s stock worth $135,000 after buying an additional 245 shares during the period. Creative Planning increased its position in shares of USANA Health Sciences by 528.0% during the second quarter. Creative Planning now owns 2,512 shares of the company’s stock worth $161,000 after buying an additional 2,112 shares during the period. SG Americas Securities LLC acquired a new stake in shares of USANA Health Sciences during the second quarter worth $162,000. Finally, Eqis Capital Management Inc. acquired a new stake in shares of USANA Health Sciences during the second quarter worth $210,000. Institutional investors own 44.62% of the company’s stock.
USNA has been the topic of a number of recent research reports. BidaskClub cut shares of USANA Health Sciences from a “hold” rating to a “sell” rating in a research note on Sunday, July 16th. Pivotal Research reduced their price objective on shares of USANA Health Sciences from $75.00 to $70.00 and set a “buy” rating on the stock in a research note on Wednesday, July 26th.
About USANA Health Sciences
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
What are top analysts saying about USANA Health Sciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for USANA Health Sciences Inc. and related companies.